Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes

OBJECTIVE This study assessed the utility of plasma fragments of propeptides of type III (PRO-C3), V (PRO-C5), and VI (PRO-C6) procollagen for the detection of liver fibrosis in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS Patients with T2DM (n = 191) underwent an oral glucose tolerance test, a liver 1H-MRS, and a liver biopsy when indicated. PRO-C3, PRO-C5, and PRO-C6 were blindly assessed. RESULTS PRO-C3 performed well for the diagnosis of moderate-to-advanced (area under the receiver operating characteristic curve [AUROC] 0.81 [95% CI 0.74–0.88]) and advanced (AUROC 0.88 [0.80–0.95]) fibrosis in T2DM patients. Its performance was similar to that of AST to platelet ratio index (APRI) (AUROC 0.83 and 0.87, respectively) and Fibrosis-4 (FIB-4) (AUROCs 0.83 and 0.86, respectively) scores. Use of PRO-C5 and PRO-C6 did not improve the accuracy to detect liver fibrosis. After 18 months, PRO-C3 changes were associated with changes in fibrosis stages. CONCLUSIONS PRO-C3 performed well for the detection of fibrosis in T2DM patients and showed promising results for prediction of histological changes in fibrosis stage with treatment.

[1]  K. Cusi,et al.  Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2019, Diabetes Care.

[2]  M. Karsdal,et al.  ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis , 2019, Hepatology.

[3]  K. Cusi,et al.  Use of a metabolomic approach to non‐invasively diagnose non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus , 2018, Diabetes, obesity & metabolism.

[4]  M. Karsdal,et al.  PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C , 2018, Scandinavian journal of gastroenterology.

[5]  P. Aschner.  F1000Prime recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. , 2017 .

[6]  K. Cusi,et al.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action , 2017, Diabetes Care.

[7]  M. Karsdal,et al.  Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[8]  M. Karsdal,et al.  Collagen Type III and VI Turnover in Response to Long-Term Immobilization , 2015, PloS one.

[9]  J. Hardies,et al.  Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[10]  B. Neuschwander‐Tetri,et al.  Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD , 2015, Diabetes Care.

[11]  M. Karsdal,et al.  Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C , 2015, Liver international (Print).

[12]  M. Karsdal,et al.  The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. , 2013, American journal of translational research.

[13]  H. Lee,et al.  Management of nonalcoholic fatty liver disease , 2013 .

[14]  Jen-Jung Pan,et al.  Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD , 2013, Biomarker Research.

[15]  M. Bulsara,et al.  Complex non‐invasive fibrosis models are more accurate than simple models in non‐alcoholic fatty liver disease , 2011, Journal of gastroenterology and hepatology.

[16]  M. Karsdal,et al.  Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[17]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.